MedPath
Found 452 clinical trials|View Analysis
Sort by:
Need a comprehensive medical report on "RNA"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals

EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

Phase 3
Completed
Conditions
Virus Diseases
Nidovirales Infections
SARS (Severe Acute Respiratory Syndrome)
RNA Virus Infections
Corona Virus Infection
Coronaviridae Infections
Respiratory Tract Infections
Respiratory Tract Diseases
Interventions
Drug: SOC
Drug: BEVA+SOC
First Posted Date
2021-03-30
Last Posted Date
2022-12-28
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
96
Registration Number
NCT04822818
Locations
🇫🇷

Hôpital TENON, Paris, France

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Phase 2
Completed
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological: BNT162b2 20mcg
Biological: BNT162b2 30mcg
Other: Placebo
First Posted Date
2021-03-25
Last Posted Date
2023-12-19
Lead Sponsor
BioNTech SE
Target Recruit Count
11837
Registration Number
NCT04816643
Locations
🇺🇸

Madera Family Medical Group, Madera, California, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

🇺🇸

SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States

and more 132 locations

PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis

Not Applicable
Terminated
Conditions
Mycobacterial Infection
Bacterial Infections
Tuberculosis, Pulmonary
Tuberculosis, Multidrug-Resistant
Interventions
Diagnostic Test: Individualised treatment duration based on RNA transcriptomic model
First Posted Date
2021-03-05
Last Posted Date
2023-12-13
Lead Sponsor
Research Center Borstel
Target Recruit Count
4
Registration Number
NCT04783727
Locations
🇩🇪

Research Center Borstel, Borstel, Schleswig-Holstein, Germany

🇷🇴

Marius Nasta Pulmonology Institute, Bucharest, Romania

🇺🇦

National Pirogov Memorial Medical University, Vinnytsia, Ukraine

and more 2 locations

Host Immune Response to Novel RNA COVID-19 Vaccination

Completed
Conditions
COVID-19 Vaccine
Cancer
Interventions
Biological: COVID-19 Vaccine
First Posted Date
2021-03-05
Last Posted Date
2023-05-25
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
50
Registration Number
NCT04784689
Locations
🇺🇸

Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

Not Applicable
Completed
Conditions
Acquired Immunodeficiency Syndrome
Virus Diseases
Sexually Transmitted Diseases, Viral
Retroviridae Infections
Human Immunodeficiency Virus
HIV Infections
RNA Virus Infections
Virus-HIV
Interventions
Behavioral: Provision of multiple self-tests
Other: Small monetary incentives
Behavioral: Use of SMS/text reminders to motivate adherence to ART or PrEP
First Posted Date
2021-02-26
Last Posted Date
2025-04-29
Lead Sponsor
University of California, San Francisco
Target Recruit Count
934
Registration Number
NCT04772469
Locations
🇰🇪

Impact Research Development Organization, Siaya, Kenya

The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma

Conditions
Pancreatic Adenocarcinoma
Interventions
Diagnostic Test: EUS FNA (endoscopic ultrasound fine needle aspiration)
First Posted Date
2021-02-21
Last Posted Date
2021-02-21
Lead Sponsor
Carol Davila University of Medicine and Pharmacy
Target Recruit Count
60
Registration Number
NCT04765410
Locations
🇷🇴

"Prof Dr Agrippa Ionescu" Emergency Hospital, Bucharest, Sector 1, Romania

🇷🇴

"Carol Davila" University Central Emergency Hospital, Bucharest, Sector 1, Romania

🇷🇴

Clinical Emergency Hospital Bucharest, Bucharest, Sector 1, Romania

and more 2 locations

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2
Conditions
Triple Negative Breast Cancer
Interventions
Drug: Personalized treatment guided by mini-PDX and RNA sequencing
First Posted Date
2021-02-09
Last Posted Date
2022-04-20
Lead Sponsor
Fudan University
Target Recruit Count
100
Registration Number
NCT04745975
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer

Conditions
Breast Cancer
Interventions
Diagnostic Test: blood sample collection.
First Posted Date
2021-01-22
Last Posted Date
2021-01-22
Lead Sponsor
Assiut University
Target Recruit Count
50
Registration Number
NCT04720508

Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19

Not Applicable
Completed
Conditions
Prenatal Stress
Covid19
Coronavirus
Maternal Complication of Pregnancy
Pregnancy Related
Neonatal Infection
Preterm Birth
Interventions
Diagnostic Test: Antibody testing for SARS-CoV-2 IgG
Diagnostic Test: Testing for SARS-CoV-2 RNA
Diagnostic Test: Testing for SARS-CoV-2 IgM/IgG
First Posted Date
2021-01-22
Last Posted Date
2025-04-03
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
448
Registration Number
NCT04718220
Locations
🇺🇸

Washington University Medical Center, St. Louis, Missouri, United States

Occult HCV Infection After DAAD Treatment in Haemodialysis Patients

Not Applicable
Completed
Conditions
Hepatitis C
Interventions
Diagnostic Test: presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .
First Posted Date
2021-01-22
Last Posted Date
2022-04-15
Lead Sponsor
Alexandria University
Target Recruit Count
30
Registration Number
NCT04719338
Locations
🇪🇬

Faculty of Medicine, Alexandria University, Alexandria, Egypt

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy